Monoclonal antibodies that are specific for vascular endothelial growth factor receptor 1 (VEGFR-1). This invention also provides nucleotide sequences encoding and amino acid sequences comprising variable heavy and light chain immunoglobulin molecules, including sequences corresponding to the complementarity determining regions of CDR1, CDR2, and CDR3. The invention also provides methods for generation and expression of anti-VEGFR-1 antibodies and methods of treating angiogenic-related disorders and reducing tumour growth by administering anti-VEGFR-1 antibodies.
